Knee Arthropathy, Lower Limb Amputation Above Knee, Lower Limb Amputation Below Knee, Mastectomy, Rotator Cuff Repair, Shoulder Arthroplasty, Skin Grafting, Upper Limb Amputation Above Elbow, Upper Limb Amputation Below Elbow, Video-Assisted Thoracoscopic Surgery (VATS)
Conditions
Brief summary
The ultimate objective of the proposed line of research is to determine if cryoanalgesia is an effective adjunctive treatment for pain in the period immediately following various painful surgical procedures; and, if this analgesic modality decreases the risk of persistent postoperative pain, or chronic pain. The objective of the proposed pilot study is to optimize the protocol and collect data to power subsequent, definitive clinical trials. Specific Aim 1: To determine if, compared with current and customary analgesia, the addition of cryoanalgesia decreases the incidence and severity of post-surgical pain. Hypothesis 1a (primary): The severity of surgically-related pain will be significantly decreased on postoperative day 2 with the addition of cryoanalgesia as compared with patients receiving solely standard-of-care treatment. Hypothesis 1b: The incidence of chronic pain will be significantly decreased one year following surgery with the addition of cryoanalgesia as compared with patients receiving solely standard-of-care treatment. Hypothesis 1c: The severity of chronic pain will be significantly decreased one year following surgery with the addition of cryoanalgesia as compared with patients receiving solely standard-of-care treatment. Specific Aim 2: To determine if, compared with current and customary analgesia, the addition of cryoanalgesia improves postoperative functioning. Hypothesis 2a: Following primary unilateral knee and shoulder arthroplasty as well as rotator cuff repair, joint range of motion will be significantly increased within the year following surgery with the addition of cryoanalgesia as compared with patients receiving solely standard-of-care treatment. Hypothesis 2b: Following video-assisted thoracoscopic surgery, inspiratory spirometry will be improved within the month following surgery with the addition of cryoanalgesia as compared with patients receiving solely standard-of-care treatment.
Detailed description
Subjects will be individuals undergoing unilateral or bilateral mastectomy; upper or lower limb amputation; primary, unilateral total knee or shoulder arthroplasty; primary, unilateral rotator cuff repair; video-assisted thoracoscopic surgery; and burn-related skin grafting of the lateral thigh. Those who consent to participate in this study will have standard preoperative peripheral nerve blocks administered and catheters inserted: paravertebral blocks or a fascial plane block (e.g., erector spinae plane block) for mastectomy, femoral/sciatic for lower limb amputation, and brachial plexus (or terminal nerves) for upper limb amputation; femoral or adductor canal for total knee arthroplasty; interscalene for shoulder arthroplasty or rotator cuff repair; thoracic epidural for video-assisted thoracoscopic surgery (VATS); and lateral femoral cutaneous nerve for skin grafting of the lateral thigh. Treatment group assignment (randomization). Subjects with successfully-administered peripheral nerve blocks (defined by sensory changes in the appropriate nerve distribution) will be allocated to one of two possible treatments: 1. cryoneurolysis 2. sham cryoneurolysis (placebo control) Randomization will be stratified by surgery type (e.g., mastectomy, upper limb amputation, and lower limb amputation). Computer-generated randomization lists will be used to create sealed, opaque randomization envelopes with the treatment group assignment enclosed in each envelope labeled with the randomization number. The specific nerves targeted will depend on the surgical site: intercostal nervesblocks (4 levels depending on the specific surgical approach) for mastectomy; femoral/sciatic for lower limb amputation, and brachial plexus (or terminal nerves) for upper limb amputation; infrapatellar branch of the saphenous nerve for knee arthroplasty; suprascapular nerve for shoulder surgery; intercostal nerves for VATS procedures, and the lateral femoral cutaneous nerve for skin grafting of the lateral thigh. The cryoneurolysis sites will be cleansed with chlorhexidine gluconate and isopropyl alcohol. Using the optimal ultrasound transducer for the specific anatomic location and subject anatomy (linear vs curvilinear array), the target nerves will be identified in a transverse cross-sectional (short axis) view. We initially used a hand-held cryoneurolysis machine (Iovera, Myoscience, Redwood City, CA; prior to merger with Pacira Pharmaceuticals). For subjects randomized to sham, we inserted the angiocatheters just through the skin and subsequently place the probe through the angiocatheter, but not deeper than immediately subcutaneous (lidocaine 2% will be administered, as needed, to anesthetize the angiocatheter track). We simulated a cryo treatment but did not actually deliver gas to the probe. Therefore, there was no temperature change. However, since all subjects had a paravertebral block in place, and intercostal cryoneurolysis approach was via the subjects' back outside of their line of vision, subjects were unable to sense much besides the pressure of the angiocatheter insertion and remained masked to treatment group. For subjects randomized to receive cryoneurolysis, the same procedure was used, only the angiocatheters inserted deeper towards the intercostal nerves, the probes situated adjacent to the intercostal nerves, and active gas passed through the probe resulting in cryoneurolysis of the target nerves. When it became available, the hand-held device was replaced by a console cryoneurolysis device. Cryoneurolysis probes are available for a console neurolysis device (PainBlocker, Epimed, Farmers Branch, Texas) that either (1) pass nitrous oxide to the tip inducing freezing temperatures; or, (2) vent the nitrous oxide at the base of the probe so that no gas reaches the probe tip, resulting in no temperature change. Importantly, these probes are indistinguishable in appearance, and therefore treating physicians, subjects, and all clinical staff will be masked to treatment group assignment \[only the treating physician/investigator performing the cryoneurolysis with be unmasked\]. An angiocatheter/introducer may be inserted beneath the ultrasound transducer and directed until the probe tip is immediately adjacent to the target nerve (lidocaine 2% will be administered, as needed, to anesthetize the angiocatheter track). The angiocatheter needle will be removed, leaving the angiocatheter through which the appropriate Epimed probe will be inserted until it is adjacent to the target nerve. The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation (active or sham) separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis. For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change. The process will be repeated with the same treatment probe for any additional nerves (e.g., all nerves will receive either active cryoneurolysis or sham/placebo, and not a mix of the two possible treatments). Statistical Analysis. The limb amputation, total knee and shoulder arthroplasty, rotator cuff repair, VATS, and skin grafting subjects will be included in pilot studies to help power a future clinical trials, so the investigators will enroll a convenience sample and not have a pre-determined primary endpoint or statistical plan. However, the end points of most interest will be average pain score on postoperative day 2 for shoulder arthroplasty and skin grafting subjects, range-of-motion at 6 weeks for the rotator cuff repairs, range-of-motion for knee arthroplasty, and FEV1 for the VATS procedures. For the subjects having mastectomy, the investigators will power this study for an acute pain end point which will provide conclusive results for that end point; but, the data will also be used to help power a subsequent large, multicenter clinical trial for a chronic pain-related end point (which will require far more subjects than the investigators will enroll for the current study). For the mastectomy subjects, sample size calculations are centered around the hypothesis that cryoneurolysis decreases the incidence and severity of post-mastectomy pain in the week following surgery. To this end, the primary outcome is the average NRS (as administered as part of the Brief Pain Inventory) queried on the afternoon of postoperative day 2. The difference in the distribution of NRS between groups will be assessed using the Mann-Whitney U test. The investigators approximate power using the two-sample t-test. Assuming a standard deviation of 2.25 NRS points, and minimum clinically meaningful difference of 2 NRS points, n=30 patients per group provide 86% power with two-sided alpha=5%. The t-test approximation was confirmed by simulating integer valued NRS scores in the range 0 to 10. One group was simulated by rounding normally distributed data with mean 1.5 and standard deviation 2.5 (resulting in median of 2 and interquartile range 0 to 3); and the other with mean 3.5 and standard deviation 2.5 (resulting in median of 4 and interquartile range 1 to 5). Note these resulting summary statistics are consistent with Ilfeld et al (2014). When 10,000 trials were simulated under these assumptions, the Mann-Whitney U test provided 89.5% power, and Type I error was maintained at 4.85%. Differences between groups in demographic variables and secondary endpoints will be assessed with the Mann-Whitney U test for continuous or ordinal data, and Fisher's Exact test for categorical data. Box-and-whisker plots will be used to visualize distributions by group. R version 3.4.4 (R-project.org) was used for sample size calculations and simulations; and the most recent version of R will be used at the time of analysis.
Interventions
Mastectomy (subjects 1-18): Myoscience Iovera device: full cryo cycle. Mastectomy (subjects 19-end) and all other procedures: Epimed PainBlocker device: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with an active probe which results in a decrease in temperature
Mastectomy (subjects 1-18): Myoscience Iovera device: simulated full cryo cycle without administering gas to the probe. Mastectomy (subjects 19-end) and all other procedures: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with a SHAM probe that does not deliver gas to the tip or result in a drop in temperature
Sponsors
Study design
Masking description
Only the investigator/physician applying the cryoneurolysis will be aware of the treatment group assignment.
Eligibility
Inclusion criteria
1. adult patients of at least 18 years of age 2. scheduled for a primary, unilateral total knee or shoulder arthroplasty, primary unilateral rotator cuff repair, VATS procedure, skin grafting of the lateral thigh, unilateral or bilateral mastectomy, or limb amputation distal to the femoral/humeral head and including at least one metatarsal/metacarpal bone 3. single-injection or continuous peripheral nerve blocks block or epidural infusion planned for perioperative analgesia 4. accepting of a cryoneurolysis procedure
Exclusion criteria
1. chronic opioid use (daily use within the 2 weeks prior to surgery and duration of use \> 4 weeks) 2. pregnancy 3. incarceration 4. inability to communicate with the investigators 5. morbid obesity (body mass index \> 40 kg/m2) 6. possessing any contraindication specific to cryoneurolysis such as a localized infection at the treatment site, cryoglobulinemia, cold urticaria and Reynaud's Syndrome
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Average Pain (Mastectomy Subjects Only) | afternoon of postoperative day 2 | Measured with the 0-10 numeric rating scale as part of the Brief Pain Inventory, with 0 equivalent to no pain and 10 equivalent to the worst imaginable pain |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Brief Pain Inventory (Interference Subscale) | Months 1, 3, 6, and 12 | The Brief Pain Inventory short form (interference scale) is designed to assess pain's impact on physical and emotional functioning. It has established reliability and validity, with minimal inter-rater discordance, and is recommended by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) consensus statement. The interference domaine is comprised of 7 questions involving the degree of pain's interference on physical and emotional functioning using a 0-10 Likert scale (0 = none; 10 = complete). The scale is thus 0-70 with higher scores equivalent to more interference due to pain\> |
| Worst Pain Measured on the 11 Point Numeric Rating Scale | Postoperative days 1, 2, 3, 4, 7, 14, and 21 | The subjects' perception of their worst level pain in the previous 24 hours measured with the 0-10 numeric rating scale as part of the Brief Pain Inventory, with 0 equivalent to no pain and 10 equivalent to the worst imaginable pain |
| Average Pain Measured on the 11 Point Numeric Rating Scale | Postoperative days 1, 2, 3, 4, 7, 14, and 21 | The subjects' perception of their average level pain in the previous 24 hours measured with the 0-10 numeric rating scale as part of the Brief Pain Inventory, with 0 equivalent to no pain and 10 equivalent to the worst imaginable pain |
| Difficultly Sleeping Due to Pain | Postoperative days 1, 2, 3, 4, 7, 14, and 21 | Difficulty sleeping due to pain (binary answer: yes or no; not based on a scale or instrument). The numbers presented in the results are the number of participants in each treatment group answering YES, they DID have difficulty sleeping due to pain |
| Number of Awakenings | Postoperative days 1, 2, 3, 4, 7, 14, and 21 | Number of awakenings from sleep due to pain (simply the number of times of awakenings--not based on a scale or instrument) |
| Nausea | Postoperative days 1, 2, 3, 4, 7, 14, and 21 | Nausea measured on a 0-10 scale with 0=no nausea and 10=vomiting; thus higher on the scale is worse |
| Analgesic Consumption | Postoperative days 1, 2, 3, 4, 7, 14, 21, as well as months 1, 3, 6, and 12 | Analgesic consumption for previous 24 hours |
| Phantom Pain Duration [Mastectomy & Amputation] | Postoperative months 1, 3, 6, and 12 | The average duration of phantom pain occurrences in the previous 3 days |
| Phantom Sensation Occurrences [Mastectomy & Amputation] | Postoperative months 1, 3, 6, and 12 | How many times in the previous 3 days subject experienced phantom sensations (the number of times experienced--not based on a scale or instrument). This outcome differs from phantom pain occurrences in that for this outcome no pain is necessary; rather, participants feel the missing body part is actually there, when it is not--yet it is not a painful sensation. |
| Phantom Sensation Duration [Mastectomy & Amputation] | Postoperative months 1, 3, 6, and 12 | The average duration of phantom sensation occurrences in the previous 3 days. This outcome differs from phantom pain duration in that for this outcome no pain is necessary; rather, participants feel the missing body part is actually there, when it is not--yet it is not a painful sensation. |
| Residual Limb or Wound Pain Occurences | Postoperative months 1, 3, 6, and 12 | How many times in the previous 3 days subject experienced residual limb or wound pain (the number of times experienced--not based on a scale or instrument) |
| Residual Limb or Wound Pain Duration | Postoperative months 1, 3, 6, and 12 | The average duration of residual limb or wound pain occurrences in the previous 3 days |
| Phantom Pain Occurences [Mastectomy & Amputation] | Postoperative months 1, 3, 6, and 12 | How many times in the previous 3 days subject experienced phantom pain (the number of times experienced--not based on a scale or instrument) |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Active Cryoneurolysis) Receiving active cryoneurolysis
Cryoneurolysis (active): Mastectomy (subjects 1-18): Myoscience Iovera device: full cryo cycle.
Mastectomy (subjects 19-end) and all other procedures: Epimed PainBlocker device: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with an active probe which results in a decrease in temperature | 51 |
| Sham Receiving sham cryoneurolysis procedure
Sham cryoneurolysis procedure: Mastectomy (subjects 1-18): Myoscience Iovera device: simulated full cryo cycle without administering gas to the probe.
Mastectomy (subjects 19-end) and all other procedures: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with a SHAM probe that does not deliver gas to the tip or result in a drop in temperature | 48 |
| Total | 99 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Postoperative Day 0 - Month 12 | Timepoints past 21 days were only for amputee and mastectomy subjects and not others | 14 | 16 |
Baseline characteristics
| Characteristic | Treatment (Active Cryoneurolysis) | Sham | Total |
|---|---|---|---|
| Age, Continuous | 51.1 years STANDARD_DEVIATION 15 | 52 years STANDARD_DEVIATION 16 | 51.5 years STANDARD_DEVIATION 15.4 |
| Body Mass Index | 25.9 kg/m^2 STANDARD_DEVIATION 4.6 | 25.0 kg/m^2 STANDARD_DEVIATION 4.5 | 25.4 kg/m^2 STANDARD_DEVIATION 4.6 |
| Height | 165.1 centimeters STANDARD_DEVIATION 8 | 165.7 centimeters STANDARD_DEVIATION 7.6 | 165.4 centimeters STANDARD_DEVIATION 7.7 |
| Race and Ethnicity Not Collected | — | — | 0 Participants |
| Sex: Female, Male Female | 40 Participants | 31 Participants | 71 Participants |
| Sex: Female, Male Male | 11 Participants | 17 Participants | 28 Participants |
| Weight | 70.6 kilograms STANDARD_DEVIATION 13.7 | 68.8 kilograms STANDARD_DEVIATION 14.8 | 69.6 kilograms STANDARD_DEVIATION 14.2 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 51 | 2 / 48 |
| other Total, other adverse events | 0 / 51 | 0 / 48 |
| serious Total, serious adverse events | 0 / 51 | 0 / 48 |
Outcome results
Average Pain (Mastectomy Subjects Only)
Measured with the 0-10 numeric rating scale as part of the Brief Pain Inventory, with 0 equivalent to no pain and 10 equivalent to the worst imaginable pain
Time frame: afternoon of postoperative day 2
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ACTIVE Cryoneurolysis | Average Pain (Mastectomy Subjects Only) | 0.0 score on a scale |
| SHAM Cryoneurolysis | Average Pain (Mastectomy Subjects Only) | 3.0 score on a scale |
Analgesic Consumption
Analgesic consumption for previous 24 hours
Time frame: Postoperative days 1, 2, 3, 4, 7, 14, 21, as well as months 1, 3, 6, and 12
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ACTIVE Cryoneurolysis | Analgesic Consumption | Postoperative Day 1 | 1.2 tablets of oxycodone (5 mg tablets) | Standard Deviation 2.3 |
| ACTIVE Cryoneurolysis | Analgesic Consumption | Postoperative Day 21 | 0.1 tablets of oxycodone (5 mg tablets) | Standard Deviation 0.5 |
| ACTIVE Cryoneurolysis | Analgesic Consumption | Postoperative Day 4 | 0.7 tablets of oxycodone (5 mg tablets) | Standard Deviation 1.5 |
| ACTIVE Cryoneurolysis | Analgesic Consumption | Postoperative Month 1 | 0 tablets of oxycodone (5 mg tablets) | Standard Deviation 0 |
| ACTIVE Cryoneurolysis | Analgesic Consumption | Postoperative Day 3 | .8 tablets of oxycodone (5 mg tablets) | Standard Deviation 1.9 |
| ACTIVE Cryoneurolysis | Analgesic Consumption | Postoperative Month 3 | 0 tablets of oxycodone (5 mg tablets) | Standard Deviation 0 |
| ACTIVE Cryoneurolysis | Analgesic Consumption | Postoperative Day 7 | 0.5 tablets of oxycodone (5 mg tablets) | Standard Deviation 1.2 |
| ACTIVE Cryoneurolysis | Analgesic Consumption | Postoperative Month 6 | 0 tablets of oxycodone (5 mg tablets) | Standard Deviation 0 |
| ACTIVE Cryoneurolysis | Analgesic Consumption | Postoperative Day 2 | 1.0 tablets of oxycodone (5 mg tablets) | Standard Deviation 1.6 |
| ACTIVE Cryoneurolysis | Analgesic Consumption | Postoperative Month 12 | 0 tablets of oxycodone (5 mg tablets) | Standard Deviation 0 |
| ACTIVE Cryoneurolysis | Analgesic Consumption | Postoperative Day 14 | 0.2 tablets of oxycodone (5 mg tablets) | Standard Deviation 0.6 |
| SHAM Cryoneurolysis | Analgesic Consumption | Postoperative Month 12 | 0 tablets of oxycodone (5 mg tablets) | Standard Deviation 0 |
| SHAM Cryoneurolysis | Analgesic Consumption | Postoperative Day 1 | 3.3 tablets of oxycodone (5 mg tablets) | Standard Deviation 4.5 |
| SHAM Cryoneurolysis | Analgesic Consumption | Postoperative Day 3 | 3.2 tablets of oxycodone (5 mg tablets) | Standard Deviation 3.7 |
| SHAM Cryoneurolysis | Analgesic Consumption | Postoperative Day 4 | 2.7 tablets of oxycodone (5 mg tablets) | Standard Deviation 3.5 |
| SHAM Cryoneurolysis | Analgesic Consumption | Postoperative Day 7 | 1.5 tablets of oxycodone (5 mg tablets) | Standard Deviation 2.2 |
| SHAM Cryoneurolysis | Analgesic Consumption | Postoperative Day 14 | 0.5 tablets of oxycodone (5 mg tablets) | Standard Deviation 1.3 |
| SHAM Cryoneurolysis | Analgesic Consumption | Postoperative Day 21 | 0.3 tablets of oxycodone (5 mg tablets) | Standard Deviation 0.8 |
| SHAM Cryoneurolysis | Analgesic Consumption | Postoperative Month 1 | 0 tablets of oxycodone (5 mg tablets) | Standard Deviation 0 |
| SHAM Cryoneurolysis | Analgesic Consumption | Postoperative Month 3 | 0 tablets of oxycodone (5 mg tablets) | Standard Deviation 0 |
| SHAM Cryoneurolysis | Analgesic Consumption | Postoperative Month 6 | 0 tablets of oxycodone (5 mg tablets) | Standard Deviation 0 |
| SHAM Cryoneurolysis | Analgesic Consumption | Postoperative Day 2 | 4.1 tablets of oxycodone (5 mg tablets) | Standard Deviation 3.8 |
Average Pain Measured on the 11 Point Numeric Rating Scale
The subjects' perception of their average level pain in the previous 24 hours measured with the 0-10 numeric rating scale as part of the Brief Pain Inventory, with 0 equivalent to no pain and 10 equivalent to the worst imaginable pain
Time frame: Postoperative days 1, 2, 3, 4, 7, 14, and 21
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ACTIVE Cryoneurolysis | Average Pain Measured on the 11 Point Numeric Rating Scale | Postoperative day 3 | 1.2 score on a scale | Standard Deviation 2.1 |
| ACTIVE Cryoneurolysis | Average Pain Measured on the 11 Point Numeric Rating Scale | Postoperative day 7 | 0.8 score on a scale | Standard Deviation 1.3 |
| ACTIVE Cryoneurolysis | Average Pain Measured on the 11 Point Numeric Rating Scale | Postoperative day 2 | 1.5 score on a scale | Standard Deviation 2 |
| ACTIVE Cryoneurolysis | Average Pain Measured on the 11 Point Numeric Rating Scale | Postoperative day 14 | 0.9 score on a scale | Standard Deviation 1.9 |
| ACTIVE Cryoneurolysis | Average Pain Measured on the 11 Point Numeric Rating Scale | Postoperative day 4 | 1.2 score on a scale | Standard Deviation 2 |
| ACTIVE Cryoneurolysis | Average Pain Measured on the 11 Point Numeric Rating Scale | Postoperative day 21 | .7 score on a scale | Standard Deviation 1.5 |
| ACTIVE Cryoneurolysis | Average Pain Measured on the 11 Point Numeric Rating Scale | Postoperative day 1 | 1.5 score on a scale | Standard Deviation 1.8 |
| SHAM Cryoneurolysis | Average Pain Measured on the 11 Point Numeric Rating Scale | Postoperative day 21 | 1.6 score on a scale | Standard Deviation 1.8 |
| SHAM Cryoneurolysis | Average Pain Measured on the 11 Point Numeric Rating Scale | Postoperative day 1 | 3.2 score on a scale | Standard Deviation 2.1 |
| SHAM Cryoneurolysis | Average Pain Measured on the 11 Point Numeric Rating Scale | Postoperative day 2 | 3.3 score on a scale | Standard Deviation 1.9 |
| SHAM Cryoneurolysis | Average Pain Measured on the 11 Point Numeric Rating Scale | Postoperative day 3 | 2.8 score on a scale | Standard Deviation 1.9 |
| SHAM Cryoneurolysis | Average Pain Measured on the 11 Point Numeric Rating Scale | Postoperative day 4 | 2.4 score on a scale | Standard Deviation 1.9 |
| SHAM Cryoneurolysis | Average Pain Measured on the 11 Point Numeric Rating Scale | Postoperative day 7 | 2 score on a scale | Standard Deviation 1.9 |
| SHAM Cryoneurolysis | Average Pain Measured on the 11 Point Numeric Rating Scale | Postoperative day 14 | 1.6 score on a scale | Standard Deviation 1.5 |
Brief Pain Inventory (Interference Subscale)
The Brief Pain Inventory short form (interference scale) is designed to assess pain's impact on physical and emotional functioning. It has established reliability and validity, with minimal inter-rater discordance, and is recommended by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) consensus statement. The interference domaine is comprised of 7 questions involving the degree of pain's interference on physical and emotional functioning using a 0-10 Likert scale (0 = none; 10 = complete). The scale is thus 0-70 with higher scores equivalent to more interference due to pain\>
Time frame: Months 1, 3, 6, and 12
Population: mastectomy and amputee participants only (other participants did not have outcome measures collected for these time points)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ACTIVE Cryoneurolysis | Brief Pain Inventory (Interference Subscale) | Month 1 | 0 units on a scale | Standard Deviation 0 |
| ACTIVE Cryoneurolysis | Brief Pain Inventory (Interference Subscale) | Month 3 | 0 units on a scale | Standard Deviation 0 |
| ACTIVE Cryoneurolysis | Brief Pain Inventory (Interference Subscale) | Month 6 | 0 units on a scale | Standard Deviation 0 |
| ACTIVE Cryoneurolysis | Brief Pain Inventory (Interference Subscale) | Month 12 | 0 units on a scale | Standard Deviation 0 |
| SHAM Cryoneurolysis | Brief Pain Inventory (Interference Subscale) | Month 12 | 0.3 units on a scale | Standard Deviation 0.9 |
| SHAM Cryoneurolysis | Brief Pain Inventory (Interference Subscale) | Month 1 | 4.1 units on a scale | Standard Deviation 9.2 |
| SHAM Cryoneurolysis | Brief Pain Inventory (Interference Subscale) | Month 6 | 1.1 units on a scale | Standard Deviation 2.3 |
| SHAM Cryoneurolysis | Brief Pain Inventory (Interference Subscale) | Month 3 | 0.6 units on a scale | Standard Deviation 2.9 |
Difficultly Sleeping Due to Pain
Difficulty sleeping due to pain (binary answer: yes or no; not based on a scale or instrument). The numbers presented in the results are the number of participants in each treatment group answering YES, they DID have difficulty sleeping due to pain
Time frame: Postoperative days 1, 2, 3, 4, 7, 14, and 21
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| ACTIVE Cryoneurolysis | Difficultly Sleeping Due to Pain | Postoperative day 3 | 6 Participants |
| ACTIVE Cryoneurolysis | Difficultly Sleeping Due to Pain | Postoperative day 7 | 4 Participants |
| ACTIVE Cryoneurolysis | Difficultly Sleeping Due to Pain | Postoperative day 2 | 6 Participants |
| ACTIVE Cryoneurolysis | Difficultly Sleeping Due to Pain | Postoperative day 14 | 4 Participants |
| ACTIVE Cryoneurolysis | Difficultly Sleeping Due to Pain | Postoperative day 4 | 3 Participants |
| ACTIVE Cryoneurolysis | Difficultly Sleeping Due to Pain | Postoperative day 21 | 4 Participants |
| ACTIVE Cryoneurolysis | Difficultly Sleeping Due to Pain | Postoperative day 1 | 5 Participants |
| SHAM Cryoneurolysis | Difficultly Sleeping Due to Pain | Postoperative day 21 | 7 Participants |
| SHAM Cryoneurolysis | Difficultly Sleeping Due to Pain | Postoperative day 1 | 11 Participants |
| SHAM Cryoneurolysis | Difficultly Sleeping Due to Pain | Postoperative day 2 | 11 Participants |
| SHAM Cryoneurolysis | Difficultly Sleeping Due to Pain | Postoperative day 3 | 13 Participants |
| SHAM Cryoneurolysis | Difficultly Sleeping Due to Pain | Postoperative day 4 | 10 Participants |
| SHAM Cryoneurolysis | Difficultly Sleeping Due to Pain | Postoperative day 7 | 11 Participants |
| SHAM Cryoneurolysis | Difficultly Sleeping Due to Pain | Postoperative day 14 | 7 Participants |
Nausea
Nausea measured on a 0-10 scale with 0=no nausea and 10=vomiting; thus higher on the scale is worse
Time frame: Postoperative days 1, 2, 3, 4, 7, 14, and 21
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ACTIVE Cryoneurolysis | Nausea | Postoperative day 1 | .5 units on a scale | Standard Deviation 1.5 |
| ACTIVE Cryoneurolysis | Nausea | Postoperative day 7 | .1 units on a scale | Standard Deviation 0.3 |
| ACTIVE Cryoneurolysis | Nausea | Postoperative day 2 | .1 units on a scale | Standard Deviation 0.5 |
| ACTIVE Cryoneurolysis | Nausea | Postoperative day 14 | 0 units on a scale | Standard Deviation 0 |
| ACTIVE Cryoneurolysis | Nausea | Postoperative day 4 | .2 units on a scale | Standard Deviation 1.1 |
| ACTIVE Cryoneurolysis | Nausea | Postoperative day 21 | 0 units on a scale | Standard Deviation 0 |
| ACTIVE Cryoneurolysis | Nausea | Postoperative day 3 | 0 units on a scale | Standard Deviation 0 |
| SHAM Cryoneurolysis | Nausea | Postoperative day 21 | 0 units on a scale | Standard Deviation 0 |
| SHAM Cryoneurolysis | Nausea | Postoperative day 1 | .6 units on a scale | Standard Deviation 2.1 |
| SHAM Cryoneurolysis | Nausea | Postoperative day 2 | .3 units on a scale | Standard Deviation 0.9 |
| SHAM Cryoneurolysis | Nausea | Postoperative day 3 | 0.3 units on a scale | Standard Deviation 1.1 |
| SHAM Cryoneurolysis | Nausea | Postoperative day 4 | .1 units on a scale | Standard Deviation 0.9 |
| SHAM Cryoneurolysis | Nausea | Postoperative day 7 | .3 units on a scale | Standard Deviation 1.7 |
| SHAM Cryoneurolysis | Nausea | Postoperative day 14 | 0 units on a scale | Standard Deviation 0 |
Number of Awakenings
Number of awakenings from sleep due to pain (simply the number of times of awakenings--not based on a scale or instrument)
Time frame: Postoperative days 1, 2, 3, 4, 7, 14, and 21
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ACTIVE Cryoneurolysis | Number of Awakenings | Postoperative day 3 | .4 Awakenings | Standard Deviation 1.2 |
| ACTIVE Cryoneurolysis | Number of Awakenings | Postoperative day 7 | .1 Awakenings | Standard Deviation 0.4 |
| ACTIVE Cryoneurolysis | Number of Awakenings | Postoperative day 2 | .3 Awakenings | Standard Deviation 1 |
| ACTIVE Cryoneurolysis | Number of Awakenings | Postoperative day 14 | .3 Awakenings | Standard Deviation 1 |
| ACTIVE Cryoneurolysis | Number of Awakenings | Postoperative day 4 | .3 Awakenings | Standard Deviation 0.9 |
| ACTIVE Cryoneurolysis | Number of Awakenings | Postoperative day 21 | .2 Awakenings | Standard Deviation 0.9 |
| ACTIVE Cryoneurolysis | Number of Awakenings | Postoperative day 1 | 0.1 Awakenings | Standard Deviation 0.6 |
| SHAM Cryoneurolysis | Number of Awakenings | Postoperative day 21 | .4 Awakenings | Standard Deviation 0.9 |
| SHAM Cryoneurolysis | Number of Awakenings | Postoperative day 1 | .8 Awakenings | Standard Deviation 1.4 |
| SHAM Cryoneurolysis | Number of Awakenings | Postoperative day 2 | .5 Awakenings | Standard Deviation 1 |
| SHAM Cryoneurolysis | Number of Awakenings | Postoperative day 3 | .9 Awakenings | Standard Deviation 1.6 |
| SHAM Cryoneurolysis | Number of Awakenings | Postoperative day 4 | .5 Awakenings | Standard Deviation 0.8 |
| SHAM Cryoneurolysis | Number of Awakenings | Postoperative day 7 | .5 Awakenings | Standard Deviation 1 |
| SHAM Cryoneurolysis | Number of Awakenings | Postoperative day 14 | .3 Awakenings | Standard Deviation 0.6 |
Phantom Pain Duration [Mastectomy & Amputation]
The average duration of phantom pain occurrences in the previous 3 days
Time frame: Postoperative months 1, 3, 6, and 12
Population: mastectomy and amputee participants only (other participants did not have outcome measures collected for these time points)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ACTIVE Cryoneurolysis | Phantom Pain Duration [Mastectomy & Amputation] | Month 1 | 0 hours | Standard Deviation 0 |
| ACTIVE Cryoneurolysis | Phantom Pain Duration [Mastectomy & Amputation] | Month 3 | 0 hours | Standard Deviation 0 |
| ACTIVE Cryoneurolysis | Phantom Pain Duration [Mastectomy & Amputation] | Month 6 | 0 hours | Standard Deviation 0 |
| ACTIVE Cryoneurolysis | Phantom Pain Duration [Mastectomy & Amputation] | Month 12 | 0 hours | Standard Deviation 0 |
| SHAM Cryoneurolysis | Phantom Pain Duration [Mastectomy & Amputation] | Month 12 | 0 hours | Standard Deviation 0.2 |
| SHAM Cryoneurolysis | Phantom Pain Duration [Mastectomy & Amputation] | Month 1 | 0.1 hours | Standard Deviation 0.2 |
| SHAM Cryoneurolysis | Phantom Pain Duration [Mastectomy & Amputation] | Month 6 | 5.1 hours | Standard Deviation 20.1 |
| SHAM Cryoneurolysis | Phantom Pain Duration [Mastectomy & Amputation] | Month 3 | 0 hours | Standard Deviation 0.2 |
Phantom Pain Occurences [Mastectomy & Amputation]
How many times in the previous 3 days subject experienced phantom pain (the number of times experienced--not based on a scale or instrument)
Time frame: Postoperative months 1, 3, 6, and 12
Population: mastectomy and amputee participants only (other participants did not have outcome measures collected for these time points)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ACTIVE Cryoneurolysis | Phantom Pain Occurences [Mastectomy & Amputation] | Month 1 | 0 Occurrences | Standard Deviation 0 |
| ACTIVE Cryoneurolysis | Phantom Pain Occurences [Mastectomy & Amputation] | Month 3 | 0 Occurrences | Standard Deviation 0 |
| ACTIVE Cryoneurolysis | Phantom Pain Occurences [Mastectomy & Amputation] | Month 6 | 0 Occurrences | Standard Deviation 0 |
| ACTIVE Cryoneurolysis | Phantom Pain Occurences [Mastectomy & Amputation] | Month 12 | 0 Occurrences | Standard Deviation 0 |
| SHAM Cryoneurolysis | Phantom Pain Occurences [Mastectomy & Amputation] | Month 12 | 0.4 Occurrences | Standard Deviation 1.2 |
| SHAM Cryoneurolysis | Phantom Pain Occurences [Mastectomy & Amputation] | Month 1 | 0.5 Occurrences | Standard Deviation 1.8 |
| SHAM Cryoneurolysis | Phantom Pain Occurences [Mastectomy & Amputation] | Month 6 | 4.0 Occurrences | Standard Deviation 1.9 |
| SHAM Cryoneurolysis | Phantom Pain Occurences [Mastectomy & Amputation] | Month 3 | 9.8 Occurrences | Standard Deviation 2.5 |
Phantom Sensation Duration [Mastectomy & Amputation]
The average duration of phantom sensation occurrences in the previous 3 days. This outcome differs from phantom pain duration in that for this outcome no pain is necessary; rather, participants feel the missing body part is actually there, when it is not--yet it is not a painful sensation.
Time frame: Postoperative months 1, 3, 6, and 12
Population: mastectomy and amputee participants only (other participants did not have outcome measures collected for these time points)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ACTIVE Cryoneurolysis | Phantom Sensation Duration [Mastectomy & Amputation] | Month 1 | 0 hours | Standard Deviation 0 |
| ACTIVE Cryoneurolysis | Phantom Sensation Duration [Mastectomy & Amputation] | Month 3 | 0 hours | Standard Deviation 0 |
| ACTIVE Cryoneurolysis | Phantom Sensation Duration [Mastectomy & Amputation] | Month 6 | 0 hours | Standard Deviation 0 |
| ACTIVE Cryoneurolysis | Phantom Sensation Duration [Mastectomy & Amputation] | Month 12 | 0 hours | Standard Deviation 0 |
| SHAM Cryoneurolysis | Phantom Sensation Duration [Mastectomy & Amputation] | Month 12 | 7.8 hours | Standard Deviation 26.8 |
| SHAM Cryoneurolysis | Phantom Sensation Duration [Mastectomy & Amputation] | Month 1 | 0 hours | Standard Deviation 0 |
| SHAM Cryoneurolysis | Phantom Sensation Duration [Mastectomy & Amputation] | Month 6 | 1.7 hours | Standard Deviation 8.9 |
| SHAM Cryoneurolysis | Phantom Sensation Duration [Mastectomy & Amputation] | Month 3 | 0.1 hours | Standard Deviation 0.3 |
Phantom Sensation Occurrences [Mastectomy & Amputation]
How many times in the previous 3 days subject experienced phantom sensations (the number of times experienced--not based on a scale or instrument). This outcome differs from phantom pain occurrences in that for this outcome no pain is necessary; rather, participants feel the missing body part is actually there, when it is not--yet it is not a painful sensation.
Time frame: Postoperative months 1, 3, 6, and 12
Population: mastectomy and amputee participants only (other participants did not have outcome measures collected for these time points)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ACTIVE Cryoneurolysis | Phantom Sensation Occurrences [Mastectomy & Amputation] | Month 1 | 0 incidences | Standard Deviation 0 |
| ACTIVE Cryoneurolysis | Phantom Sensation Occurrences [Mastectomy & Amputation] | Month 3 | 0 incidences | Standard Deviation 0 |
| ACTIVE Cryoneurolysis | Phantom Sensation Occurrences [Mastectomy & Amputation] | Month 6 | 0 incidences | Standard Deviation 0 |
| ACTIVE Cryoneurolysis | Phantom Sensation Occurrences [Mastectomy & Amputation] | Month 12 | 0 incidences | Standard Deviation 0 |
| SHAM Cryoneurolysis | Phantom Sensation Occurrences [Mastectomy & Amputation] | Month 12 | 10.3 incidences | Standard Deviation 26.7 |
| SHAM Cryoneurolysis | Phantom Sensation Occurrences [Mastectomy & Amputation] | Month 1 | 0 incidences | Standard Deviation 0 |
| SHAM Cryoneurolysis | Phantom Sensation Occurrences [Mastectomy & Amputation] | Month 6 | 0.5 incidences | Standard Deviation 1.7 |
| SHAM Cryoneurolysis | Phantom Sensation Occurrences [Mastectomy & Amputation] | Month 3 | 1.2 incidences | Standard Deviation 3.1 |
Residual Limb or Wound Pain Duration
The average duration of residual limb or wound pain occurrences in the previous 3 days
Time frame: Postoperative months 1, 3, 6, and 12
Population: mastectomy and amputee participants only (other participants did not have outcome measures collected for these time points)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ACTIVE Cryoneurolysis | Residual Limb or Wound Pain Duration | Month 3 | 0 hours | Standard Deviation 0 |
| ACTIVE Cryoneurolysis | Residual Limb or Wound Pain Duration | Month 1 | 0.1 hours | Standard Deviation 0.3 |
| ACTIVE Cryoneurolysis | Residual Limb or Wound Pain Duration | Month 6 | 0 hours | Standard Deviation 0.2 |
| ACTIVE Cryoneurolysis | Residual Limb or Wound Pain Duration | Month 12 | 0 hours | Standard Deviation 0 |
| SHAM Cryoneurolysis | Residual Limb or Wound Pain Duration | Month 12 | 0 hours | Standard Deviation 0.2 |
| SHAM Cryoneurolysis | Residual Limb or Wound Pain Duration | Month 6 | 5.3 hours | Standard Deviation 20.1 |
| SHAM Cryoneurolysis | Residual Limb or Wound Pain Duration | Month 1 | 17.6 hours | Standard Deviation 37.8 |
| SHAM Cryoneurolysis | Residual Limb or Wound Pain Duration | Month 3 | 3.5 hours | Standard Deviation 18.4 |
Residual Limb or Wound Pain Occurences
How many times in the previous 3 days subject experienced residual limb or wound pain (the number of times experienced--not based on a scale or instrument)
Time frame: Postoperative months 1, 3, 6, and 12
Population: mastectomy and amputee participants only (other participants did not have outcome measures collected for these time points)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ACTIVE Cryoneurolysis | Residual Limb or Wound Pain Occurences | Month 1 | 0.9 Occurrences | Standard Deviation 1.6 |
| ACTIVE Cryoneurolysis | Residual Limb or Wound Pain Occurences | Month 3 | 0 Occurrences | Standard Deviation 0 |
| ACTIVE Cryoneurolysis | Residual Limb or Wound Pain Occurences | Month 6 | 0.1 Occurrences | Standard Deviation 0.4 |
| ACTIVE Cryoneurolysis | Residual Limb or Wound Pain Occurences | Month 12 | 0.1 Occurrences | Standard Deviation 0.4 |
| SHAM Cryoneurolysis | Residual Limb or Wound Pain Occurences | Month 12 | 1.1 Occurrences | Standard Deviation 3.4 |
| SHAM Cryoneurolysis | Residual Limb or Wound Pain Occurences | Month 1 | 20 Occurrences | Standard Deviation 37.1 |
| SHAM Cryoneurolysis | Residual Limb or Wound Pain Occurences | Month 6 | 5.3 Occurrences | Standard Deviation 18.4 |
| SHAM Cryoneurolysis | Residual Limb or Wound Pain Occurences | Month 3 | 4.4 Occurrences | Standard Deviation 18.4 |
Worst Pain Measured on the 11 Point Numeric Rating Scale
The subjects' perception of their worst level pain in the previous 24 hours measured with the 0-10 numeric rating scale as part of the Brief Pain Inventory, with 0 equivalent to no pain and 10 equivalent to the worst imaginable pain
Time frame: Postoperative days 1, 2, 3, 4, 7, 14, and 21
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ACTIVE Cryoneurolysis | Worst Pain Measured on the 11 Point Numeric Rating Scale | Postoperative Day 3 | 2.8 score on a scale | Standard Deviation 2.7 |
| ACTIVE Cryoneurolysis | Worst Pain Measured on the 11 Point Numeric Rating Scale | Postoperative Day 7 | 2.4 score on a scale | Standard Deviation 2.4 |
| ACTIVE Cryoneurolysis | Worst Pain Measured on the 11 Point Numeric Rating Scale | Postoperative Day 2 | 3.3 score on a scale | Standard Deviation 2.9 |
| ACTIVE Cryoneurolysis | Worst Pain Measured on the 11 Point Numeric Rating Scale | Postoperative Day 14 | 1.6 score on a scale | Standard Deviation 2.4 |
| ACTIVE Cryoneurolysis | Worst Pain Measured on the 11 Point Numeric Rating Scale | Postoperative Day 4 | 2.4 score on a scale | Standard Deviation 2.6 |
| ACTIVE Cryoneurolysis | Worst Pain Measured on the 11 Point Numeric Rating Scale | Postoperative Day 21 | 1.4 score on a scale | Standard Deviation 2.6 |
| ACTIVE Cryoneurolysis | Worst Pain Measured on the 11 Point Numeric Rating Scale | Postoperative Day 1 | 3.7 score on a scale | Standard Deviation 2.5 |
| SHAM Cryoneurolysis | Worst Pain Measured on the 11 Point Numeric Rating Scale | Postoperative Day 21 | 3.0 score on a scale | Standard Deviation 2.5 |
| SHAM Cryoneurolysis | Worst Pain Measured on the 11 Point Numeric Rating Scale | Postoperative Day 1 | 5.5 score on a scale | Standard Deviation 2.4 |
| SHAM Cryoneurolysis | Worst Pain Measured on the 11 Point Numeric Rating Scale | Postoperative Day 2 | 5.6 score on a scale | Standard Deviation 2.7 |
| SHAM Cryoneurolysis | Worst Pain Measured on the 11 Point Numeric Rating Scale | Postoperative Day 3 | 5.1 score on a scale | Standard Deviation 2.8 |
| SHAM Cryoneurolysis | Worst Pain Measured on the 11 Point Numeric Rating Scale | Postoperative Day 4 | 4.3 score on a scale | Standard Deviation 2.7 |
| SHAM Cryoneurolysis | Worst Pain Measured on the 11 Point Numeric Rating Scale | Postoperative Day 7 | 3.7 score on a scale | Standard Deviation 2.4 |
| SHAM Cryoneurolysis | Worst Pain Measured on the 11 Point Numeric Rating Scale | Postoperative Day 14 | 3.1 score on a scale | Standard Deviation 2.3 |